What is the medical insurance reimbursement price for Sotorasibu?

Sotorasib is an innovative KRAS G12C inhibitor, mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. KRASmutations are common in lung cancer, but due to the KRASgene’s “undruggable”characteristics, there has been a lack of effective targeted treatment options in the past few decades. Sotoracib selectively binds to the KRAS G12C mutated protein and inhibits its activity, thus blocking the proliferation and growth of cancer cells, bringing a new treatment method to patients with advanced lung cancer. Its clinical data shows that sotoraxib can significantly prolong the progression-free survival of patients and achieve good response rates in previously treated patients, which is especially suitable for patients after multiple lines of treatment.

Currently, sotorasibu is not yet available in mainland China, so domestic patients cannot purchase it directly, and it is not yet included in the scope of national medical insurance reimbursement. However, patients can choose to purchase sotoraxib through overseas channels, including obtaining original drugs or generic drugs. The price of the original drug Sotorasibu is relatively high overseas. Depending on the region, the price of the European version and the Hong Kong version is usually tens of thousands of yuan, which is not a small burden for patients.

In order to solve this problem, some countries and regions, such as Laos and India, have launched generic drugs of sotorasibu. These generic drugs are consistent with the original drugs in terms of ingredients and mechanism of action. The current price of the generic sotorasibu produced by Lucius and Big Bear Pharmaceuticals in Laos is around more than 1,000 yuan to more than 2,000 yuan. This undoubtedly provides a more economical option for patients who need long-term medication and reduces the cost of treatment.

In the future, sotorasibu is more likely to be launched in China. If it is successfully launched and qualified for medical insurance reimbursement, it will significantly reduce the financial burden on patients. However, the determination of medical insurance reimbursement prices needs to take into account factors such as drug price negotiations and patient demand. Therefore, even if it is launched, it will take some time to be included in medical insurance. Domestic patients still need to rely on overseas purchases of drugs to maintain treatment, and the option of generic drugs allows more patients to afford the cost of this innovative treatment.